Literature DB >> 22206940

Fluorescent reporters of thrombin, heparin cofactor II, and heparin binding in a ternary complex.

Ingrid M Verhamme1.   

Abstract

Thrombin inactivation by heparin cofactor II (HCII) is accelerated by ternary complex formation with heparin. The novel active-site-labeled thrombins, [4'F]FPR-T and [6F]FFR-T, and the exosite I probe, Hir-(54-65)(SO₃⁻), characterized thrombin exosite I and II interactions with HCII and heparin in the complex. HCII binding to exosite I of heparin-bound [4'F]FPR-T caused a saturable fluorescence increase, absent with antithrombin. Heparin binding to exosite II and a second weaker site caused fluorescence quenching of [6F]-FFR-T, attenuated by simultaneous Hir-(54-65)(SO₃⁻) binding. Stopped-flow analysis demonstrated ordered assembly of HCII and the [6F]FFR-T·heparin complex, in agreement with tighter heparin binding to thrombin than to HCII. Saturating HCII dependences and bell-shaped heparin dependences of the fluorescence change reported ternary complex formation, consistent with a template mechanism in which the thrombin·heparin complex binds HCII and allowing for interaction of thrombin·(heparin)₂ complexes with HCII. Hir-(54-65)(SO₃⁻) displacement in reactions with FPR-blocked and active thrombin indicated a concerted action of the active site and exosite I during ternary complex formation. These studies demonstrate that binding of HCII to the thrombin·heparin complex is dramatically enhanced compared with heparin binding alone and that exosite I is still available for ligand or HCII binding when both heparin binding sites on thrombin are saturated.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22206940      PMCID: PMC3461310          DOI: 10.1016/j.ab.2011.11.021

Source DB:  PubMed          Journal:  Anal Biochem        ISSN: 0003-2697            Impact factor:   3.365


  58 in total

1.  Glycosaminoglycan-binding properties and kinetic characterization of human heparin cofactor II expressed in Escherichia coli.

Authors:  Suryakala Sarilla; Sally Y Habib; Douglas M Tollefsen; David B Friedman; Diana R Arnett; Ingrid M Verhamme
Journal:  Anal Biochem       Date:  2010-07-27       Impact factor: 3.365

2.  The interaction of thrombin and heparin. Proflavine dye binding studies.

Authors:  E H Li; C Orton; R D Feinman
Journal:  Biochemistry       Date:  1974-11-19       Impact factor: 3.162

3.  Crystal structures of native and thrombin-complexed heparin cofactor II reveal a multistep allosteric mechanism.

Authors:  Trevor P Baglin; Robin W Carrell; Frank C Church; Charles T Esmon; James A Huntington
Journal:  Proc Natl Acad Sci U S A       Date:  2002-08-08       Impact factor: 11.205

4.  Heparin cofactor II is regulated allosterically and not primarily by template effects. Studies with mutant thrombins and glycosaminoglycans.

Authors:  J P Sheehan; D M Tollefsen; J E Sadler
Journal:  J Biol Chem       Date:  1994-12-30       Impact factor: 5.157

5.  The N-terminal acidic domain of heparin cofactor II mediates the inhibition of alpha-thrombin in the presence of glycosaminoglycans.

Authors:  V M Van Deerlin; D M Tollefsen
Journal:  J Biol Chem       Date:  1991-10-25       Impact factor: 5.157

6.  Further characterization of the antithrombin-binding sequence in heparin.

Authors:  L Thunberg; G Bäckström; U Lindahl
Journal:  Carbohydr Res       Date:  1982-03-01       Impact factor: 2.104

7.  The refined 1.9-A X-ray crystal structure of D-Phe-Pro-Arg chloromethylketone-inhibited human alpha-thrombin: structure analysis, overall structure, electrostatic properties, detailed active-site geometry, and structure-function relationships.

Authors:  W Bode; D Turk; A Karshikov
Journal:  Protein Sci       Date:  1992-04       Impact factor: 6.725

8.  Rapid-reaction kinetic characterization of the pathway of streptokinase-plasmin catalytic complex formation.

Authors:  Ingrid M Verhamme; Paul E Bock
Journal:  J Biol Chem       Date:  2008-07-25       Impact factor: 5.157

9.  Structure of the antithrombin-thrombin-heparin ternary complex reveals the antithrombotic mechanism of heparin.

Authors:  Wei Li; Daniel J D Johnson; Charles T Esmon; James A Huntington
Journal:  Nat Struct Mol Biol       Date:  2004-08-15       Impact factor: 15.369

10.  The heparin binding properties of heparin cofactor II suggest an antithrombin-like activation mechanism.

Authors:  Denis O'Keeffe; Steven T Olson; Nijole Gasiunas; John Gallagher; Trevor P Baglin; James A Huntington
Journal:  J Biol Chem       Date:  2004-09-15       Impact factor: 5.157

View more
  2 in total

1.  A Translational Quantitative Systems Pharmacology Model for CD3 Bispecific Molecules: Application to Quantify T Cell-Mediated Tumor Cell Killing by P-Cadherin LP DART®.

Authors:  Alison Betts; Nahor Haddish-Berhane; Dhaval K Shah; Piet H van der Graaf; Frank Barletta; Lindsay King; Tracey Clark; Cris Kamperschroer; Adam Root; Andrea Hooper; Xiaoying Chen
Journal:  AAPS J       Date:  2019-05-22       Impact factor: 4.009

Review 2.  Mechanistic Quantitative Pharmacology Strategies for the Early Clinical Development of Bispecific Antibodies in Oncology.

Authors:  Alison Betts; Piet H van der Graaf
Journal:  Clin Pharmacol Ther       Date:  2020-07-20       Impact factor: 6.875

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.